Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow UroGen Pharma Ltd.

Get SEC filing alerts via email and in your feed for UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

About UroGen Pharma Ltd.

UroGen Pharma develops innovative, proprietary drug delivery solutions for uro-oncology and urological cancers. Its core technology, RTGel, enables sustained, targeted release of existing and investigational drugs like mitomycin, aiming to improve efficacy and reduce invasiveness of treatments for conditions such as UTUC and bladder cancer. The company focuses on minimally invasive therapies, leveraging its strong IP portfolio and regulatory expertise to address unmet medical needs in the urinary tract.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from UroGen Pharma Ltd.

1
1
UroGen Pharma Ltd. UroGen Pharma Reports 153% Revenue Growth to $50.96 Million in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
UroGen Pharma Ltd. UroGen Pharma Reports $109.8 Million Revenue and $153.5 Million Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
UroGen Pharma Ltd. UroGen Pharma Reports $27.5M Revenue in Q3 2025, Net Loss Increases to $33.3M

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
UroGen Pharma Ltd. UroGen Pharma Reports 10.8% Revenue Growth but Incurred $49.9 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
UroGen Pharma Ltd. UroGen Pharma Reports $20.3 Million Revenue in Q1 2025, 7.8% Increase Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
UroGen Pharma Ltd. UroGen Pharma Reports $126.8 Million Net Loss for 2024, Revenue Increases to $90.4 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
UroGen Pharma Ltd. UroGen Pharma Reports Increased Revenue and Assets, Widening Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments